Table 1 Basic characteristic of head and neck primary cancer patients receiving pulmonary metastasectomya.

From: Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy

Characteristic

HNSCC

NPC

TC

ACC

P value

(N = 20)

(N = 7)

(N = 16)

(N = 3)

General information

   Age on resected date ≥60 (years)

6 (30.0)

2 (28.6)

5 (31.3)

0 (0.0)

0.733

   Male

20 (100.0)

5 (71.4)

8 (50.0)

0 (0.0)

<0.001

Primary tumor location

    

<0.001

   Oral cavity

2 (10.0)

0 (0.0)

0 (0.0)

1 (33.3)

 

   Nasopharynx

0 (0.0)

7 (100.0)

0 (0.0)

0 (0.0)

 

   Oropharynx

8 (40.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   Hypopharynx

8 (40.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   Larynx

2 (10.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   Thyroid

0 (0.0)

0 (0.0)

16 (100.0)

0 (0.0)

 

   Other

0 (0.0)

0 (0.0)

0 (0.0)

2 (66.7)b

 

   Unknown

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

Initial clinical stagingc

   T staging ≥ 3

11/16 (68.8)

3/6 (50.0)

6/10 (60.0)

0/1 (0.0)

0.451

   N staging positive

15/17 (88.2)

5/6 (88.3)

5/10 (50.0)

0/1 (0.0)

0.072

Initial treatment

    

<0.001

   Curative CRT

0 (0.0)

2 (28.6)

0 (0.0)

0 (0.0)

 

   Curative radiotherapy alone

0 (0.0)

1 (14.3)

0 (0.0)

0 (0.0)

 

   IC followed with curative CRT

2 (10.0)

2 (28.6)

0 (0.0)

0 (0.0)

 

   IC followed with curative radiotherapy

1 (5.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   IC followed with curative surgery and adjuvant CRT

1 (5.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   Curative surgery

3 (15.0)

0 (0.0)

14 (87.5)

1 (33.3)

 

   Curative surgery followed with adjuvant CRT

7 (35.0)

0 (0.0)

0 (0.0)

2 (66.7)

 

   Curative surgery followed with adjuvant radiotherapy

3 (15.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

   Palliative therapy

3 (15.0)

2 (28.6)

2 (12.5)

0 (0.0)

 

Pathologic feature of curative surgeryc

   Extracapsular spread

8/11 (72.7)

N/A

2/5 (40.0)

0 (0.0)

0.242

   Margin ≤ 0.5 cm

8/11 (72.7)

N/A

6/8 (75.0)

1/1 (100.0)

0.834

   Lymphovascular invasion

7/12 (58.3)

N/A

4/8 (50.0)

1/1 (100.0)

0.198

   Perineural invasion

6/12 (50.0)

N/A

0/7 (0.0)

1/1 (100.0)

0.024

   p16INK4A

1/4 (25.0)

N/A

N/A

N/A

N/A

Time to distal metastasis after curative treatment ≤ 12 monthsd

12/17 (70.1)

0/5 (0.0)

5/14 (35.7)

0/3 (0.0)

0.009

Pulmonary metastatic number ≥ 2

8 (40.0)

2 (28.6)

10 (62.5)

2 (66.7)

0.342

Bilateral pulmonary metastases

6 (30.0)

0 (0.0)

0 (0.0)

2 (66.7)

0.007

Pathologic features of matched pulmonary metastatic sample

   Tumor size ≥2 cm

11 (55.0)

5 (71.4)

5 (31.3)

2 (66.7)

0.254

   Margin ≤0.5 cm

10 (50.0)

5 (71.4)

8 (72.7)

1 (33.3)

0.427

   Mediastinum organ involvement

3 (15.0)

1 (14.3)

3 (18.8)

0 (0.0)

0.874

Smokingc

   Yes, but quit after diagnosis

8/17 (47.1)

N/A

N/A

N/A

N/A

   Yes, and persisted during treatment

2/17 (11.8)

N/A

N/A

N/A

N/A

   No

7/17 (41.2)

N/A

N/A

N/A

N/A

  1. aThree salivary gland carcinoma patients with histological types of adenocarcinoma, sarcomatoid carcinoma, and undifferentiated carcinoma were excluded.
  2. bOne from nasal sinus and another from salivary gland.
  3. cDenominator was the available patients to be evaluated.
  4. dPatients with initial distant metastasis were excluded. The time to distal metastasis data for thyroid carcinoma patients diagnosed outside of our hospital were unavailable.
  5. Abbreviations: HNSCC, head neck squamous cell carcinoma; NPC, nasopharyngeal carcinoma; TC, thyroid carcinoma; ACC, adenoid cystic carcinoma; IC, induction chemotherapy; CRT, chemoradiotherapy.
Back to article page